Based on these findings we predicted that inhibition of ERBB1/2/4 using neratinib or inhibition of c-MET using crizotinib would block compensatory survival signaling and enhance the anti-tumor efficacy of [pazopanib + entinostat]. This evidence concerns the gene MET and neoplasm.